Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.6% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 2

3(42.9%)

Phase 1

1(14.3%)

7Total

Phase 3(3)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04090736Phase 3Active Not Recruiting

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Role: collaborator

NCT04107727Phase 2Completed

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Role: collaborator

NCT05788497Phase 3Terminated

Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids

Role: collaborator

NCT04810390Phase 3Completed

Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

Role: collaborator

NCT04186013Phase 2Active Not Recruiting

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Role: collaborator

NCT04445272Phase 2Completed

Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia

Role: collaborator

NCT02340936Phase 1Completed

Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma

Role: collaborator

All 7 trials loaded